HURA TuHURA Biosciences, Inc./NV
Pharmaceutical Preparations · Nasdaq · SEC CIK 1498382 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-2.2%
TTM EPS YoY-47.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-167.5%
ROA-96.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets47.7%
Debt / equity0.49x
Current ratio0.47x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.79x
Accruals ratio-20.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20242024-06-30 | FY20242023-12-31 | FY20232023-06-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $0 | — | $0 | — |
| R&D expense | $20.53M | $13.34M | $2.66M | $9.40M | $9.31M |
| SG&A expense | $7.58M | $3.87M | $5.79M | $4.14M | $5.49M |
| Interest expense | $625,283 | $4.14M | — | $18,688 | — |
| Pretax income | -$30.05M | -$21.68M | — | $29.30M | — |
| Income tax | $1,600 | $3,768 | — | $0 | — |
| Net income | -$30.05M | -$21.68M | -$8.32M | -$29.32M | -$14.65M |
| EPS (basic) | -0.63 | -1.21 | -0.32 | -2.47 | -9.27 |
| EPS (diluted) | -0.63 | -1.21 | — | -2.47 | — |
| Weighted avg. shares (diluted) | 47.93M | 18.66M | — | 11.89M | — |
| Balance sheet | |||||
| Cash & equivalents | $3.62M | $12.66M | $12.31M | $3.67M | $1.53M |
| Current assets | $4.62M | $19.61M | $5.53M | $4.16M | $3.27M |
| PP&E, net | $300,639 | $123,366 | $674,000 | $182,170 | $709,000 |
| Goodwill | $10.74M | — | — | — | — |
| Total assets | $27.35M | $19.97M | $6.20M | $4.36M | $3.98M |
| Current liabilities | $5.92M | $5.33M | $2.26M | $3.60M | $3.08M |
| Total liabilities | $6.42M | $5.37M | $2.44M | $5.92M | $3.25M |
| Shareholders' equity | $20.93M | $14.59M | -$6.96M | -$1.56M | $731,000 |
| Shares outstanding | 59.34M | 12.17M | — | 12.17M | — |
| Cash flow statement | |||||
| Operating cash flow | -$27.63M | -$14.73M | -$7.18M | -$11.95M | -$11.87M |
| Capital expenditure | $76,083 | $57,906 | — | $79,224 | — |
| Free cash flow | -$27.71M | -$14.79M | — | -$12.03M | — |
| Investing cash flow | -$1.34M | -$6.05M | -$20,000 | -$1.30M | -$232,000 |
| Financing cash flow | $19.93M | $29.77M | $10.57M | $2.66M | $1.85M |
| Depreciation & amortization | $71,265 | $116,710 | $55,000 | $177,377 | $60,000 |
| Stock-based compensation | $6.42M | $1.96M | $607,000 | $478,890 | $1.49M |
| Share buybacks | — | — | — | $24,751 | — |
Free plan shows the latest 5 periods; Pro shows all 19 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.